

Strategies to Integrate Exposure,
PBPK Models and Data on
Metabolism to Predict Plasma Levels
of Compounds and their Metabolites
that are Directly Comparable to *In
Vitro* Toxicology Results

Tim Pastoor, Syngenta

On behalf of

Paul Price, The Dow Chemical Company

Paul Price



Measurement of dose in toxicology is now divided



©OW CONFIDENTIAL

Measurement of dose in toxicology is now divided

Internal
Concentration


μM

Future

Admin.
Dose

$\text{mg}/\text{kg}/\text{d}$

Traditional



©OW CONFIDENTIAL

Measurement of dose in toxicology is now divided

Internal
Concentration

μM

Future

In-vitro based tox

Admin.

Dose

$\text{mg}/\text{kg}/\text{d}$

Traditional

Animal-based tox

©OW CONFIDENTIAL

Measurement of dose in toxicology is now divided

Internal
Concentration

μM

Future

In-vitro based tox

Relevant to
biomonitoring

Admin.

Dose

$\text{mg}/\text{kg}/\text{d}$

Traditional

Animal-based tox

Linked to traditional
exposure and risk
assessments

©OW CONFIDENTIAL

Measurement of dose in toxicology is now divided

Internal Concentration

μM

Future

In-vitro based tox

Relevant to biomonitoring

Integrates doses from multiple routes and time-varying exposures

Admin.

Dose

$\text{mg}/\text{kg}/\text{d}$

Traditional

Animal-based tox

Linked to traditional exposure and risk assessments

Avoids dealing with ADME

©OW CONFIDENTIAL

Internal
Concentration
 μM

Admin.
Dose
 $\text{mg}/\text{kg}/\text{d}$



Our current approach for connecting the two dose metrics (reverse dosimetry) can only predict the relationship under restricted circumstances (steady state conditions) and for limited numbers of chemicals

Goals of Project

- Goal 1:
 - Tiered high throughput tools
 - Predict the time course of blood concentrations
- Goal 2: Metabolism in HTS risk assessments
 - Which chemicals
 - Assays

Resources

- Government, academia, and industry recognize the need to better connect internal and administered doses.
- Publications.
- RISK21 IVIVE subgroup.
- Structure-based predictions of metabolism and parameters required by PK and PBPK models are becoming more available.

Benefits

- Improved HTS risk assessments
 - More effective screening out low concern uses of specific chemicals
 - Ability to identify chemical-specific critical data for performing higher-tiered assessments
- Coordinate and establish best practices for the various groups working in this area.

Internal
Concentration
 μM

Admin.
Dose
 $\text{mg}/\text{kg}/\text{d}$



Strategies to Integrate Exposure, PBPK Models and Data on Metabolism to Predict Plasma Levels of Compounds and their Metabolites that are Directly Comparable to *In Vitro* Toxicology Results

©OW CONFIDENTIAL